CTOs on the Move

Baby and Company

www.babyandcompany.com

 
At Baby+Company we want to change the world one birth at a time… We`re driven by a passion to expand women`s choices -to make what can feel like a choice between two extremes, hospital delivery and home birth, into a spectrum of options. Not because we don`t support these other models of care, but because for many women, neither feels like the right fit. So we`re building birth centers that celebrate the individuality of our families— through a model of care that brings together the centuries-old tradition of midwifery with the very best research, resources and data available today.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Peace River Community Services

Peace River Community Services is a Grande Prairie, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stallion Technologies Inc

Stallion Technologies Inc is a Syracuse, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Northwestern University Clinical andTranslational Sciences Institute (NUCATS)

NUCATS provides scientists with consultative resources and expertise in order to accelerate how quickly transformative scientific discoveries make their way to patients and the community. It is our goal to continually increase the quality, safety, efficiency and speed of innovative clinical and translational research.

Penn State Health Milton S. Hershey Medical Center

Penn State Health Milton S. Hershey Medical Center, Penn State College of Medicine and The Children`s Hospital at Penn State Health Milton S. Hershey Medical Center are committed to enhancing the quality of life through improved health, the professional preparation of those who will serve the health needs of others, and the discovery of knowledge that will benefit all.

Avaxia Biologics

Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.